

MEDICAMEN Biotech Limited




Regd. Office :
10, Community Centre No. 2,
Ashok Vihar, Phase-II,
Delhi-110052

CIN NO L74899DL1993PLC056594

Tel. : 27463506, 47589500
Toll Free No. : 1800 3000 7889,
1800 1029 010
Fax : 011-27138171
Web : www.medicamen.com

Audited Financial Results for the Year ended 31st March 2014					
PART I Particulars	(Rupees in Lakh)				
	Quarter Ended			Year Ended	
	31/03/2014 Audited	31/12/2013 Unaudited	31/03/2013 Audited	31/03/2014 Audited	31/03/2013 Audited
01. Income					
(a) Net Sales/Income from operations (Net of excise duty)	2239.17	1201.80	1853.81	7324.86	6399.79
(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00
(c) Total Income from Operations (Net)	2239.17	1201.80	1853.81	7324.86	6399.79
02. Expenses					
(a) Cost of Material Consumed	1549.64	714.21	1271.83	4444.06	4427.27
(b) Purchase of Goods Traded/ Stock-in- trade	102.45	86.20	61.29	349.96	184.18
(c) Changes in inventory of Finished Goods, Work-in- Progress & Stock-in-trade	(43.99)	(44.62)	4.88	148.89	(73.95)
(d) Employees Benefits Expenses	138.15	138.86	195.35	557.56	727.73
(e) Depreciation & Amortisation Expenses	39.90	40.43	39.14	160.94	157.69
(f) Other expenses	464.12	254.50	317.84	1416.61	1277.10
TOTAL EXPENSES	2250.26	1189.58	1944.32	7078.00	6700.02
03. Profit/(Loss) from Operations before Other Income, Finance Cost & Exceptional Items (1-2)	(11.10)	12.22	(90.51)	246.86	(300.23)
04. Other Income	39.00	7.80	30.74	60.62	73.20
05. Profit/(Loss) from ordinary activities before Finance Cost & Exceptional Items (3+4)	27.91	20.03	(59.77)	307.48	(277.03)
06. Finance Cost	77.51	72.05	70.55	289.61	260.53
07. Profit/(Loss) from ordinary activities after Finance Cost but before Exceptional Items (5-6)	(49.61)	(52.03)	(130.32)	17.87	(487.56)
08. Exceptional Items	0.00	0.00	0.00	0.00	0.00
09. Profit/(Loss) from Ordinary Activities before tax (7+8)	(49.61)	(52.03)	(130.32)	17.87	(487.56)
10. Tax Expenses					
Current Year	(9.45)	(9.91)	0.00	3.41	0.00
Tax Related to Earlier Year	0.00	0.00	0.00	0.00	0.00
Deferred Tax Liability	4.22	0.63	(3.69)	5.05	5.21
11. Net Profit/(Loss) from Ordinary Activities After Tax (9-10)	(44.38)	(42.74)	(126.63)	9.42	(492.76)
12. Extraordinary Items (Net of Tax expenses)	-	-	-	-	-
13. Net Profit/(Loss) for the period (11-12)	(44.38)	(42.74)	(126.63)	9.42	(492.76)
14. Paid-up equity share capital (Rs.10/- per share)	891.36	849.00	849.00	891.36	849.00
15. Reserve excluding revaluation reserves	-	-	-	736.40	722.47
16. Earning Per Share before & after Extra Ordinary Items (Rs.) (not annualised)					
(a) Basic	(0.52)	(0.50)	(1.51)	0.11	(5.88)
(b) Diluted	(0.52)	(0.50)	(1.51)	0.11	(5.88)

For Medicamen Biotech Ltd.



(B.K. Gupta)
Managing Director

PART II					
Select Information for the Quarter ended 31st March, 2014					
A. Particulars of Shareholding					
1. Public Shareholding					
- No. of Shares	5143518	5174591	5184912	5143518	5184912
- Percentage of Shareholding	57.70	60.95	61.07	57.70	61.07
2. Promoters & Promoter Group Shareholding					
a) Pledged/Encumbered					
- Number of Shares	1861200	1861200	1861200	1861200	1861200
- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	49.37	56.14	56.31	49.37	56.31
- Percentage of Shares (as a % of the total share capital of the company)	20.88	21.92	21.92	20.88	21.92
b) Non-encumbered					
- Number of Shares	1908888	1454209	1443888	1908888	1443888
- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	50.63	43.86	43.69	50.63	43.69
- Percentage of Shares (as a % of the total share capital of the company)	21.42	17.13	17.01	21.42	17.01

B. Investor Complaints	3 Months ended 31/03/2014
Pending at the beginning of the quarter	Nil
Received during the quarter	2
Disposed of during the quarter	2
Remaning unresolved at the end of the quarter	Nil

STATEMENT OF ASSETS & LIABILITIES			
	Particulars	As At	
		31/03/2014 Audited	31/03/2013 Audited
A	EQUITY AND LIABILITIES		
1	Shareholders' Fund		
	(a) Share Capital	891.36	849.00
	(b) Reserves and Surplus	736.40	722.74
	(c) Money Received against Share Warrants	26.05	0.00
		1653.81	1571.74
2	Non-current Liabilities		
	(a) Long-term borrowings	15.52	16.30
	(b) Deferred Tax liabilities (Net)	99.73	94.68
	(d) Long-term Provisions	128.18	67.62
		243.42	178.60
3	Current Liabilities		
	(a) Short term borrowings	1512.60	1662.54
	(b) Trade payables	2834.89	2801.57
	(c) Other current liabilities	200.54	238.99
	(d) Short term provisions	12.63	69.98
		4560.66	4773.08
	TOTAL- EQUITY AND LIABILITIES	6457.89	6523.42
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets		
	(i) Tangible assets		
	(ii) Intangible assets	2168.73	2283.90
	(iii) Capital work-in-progress	7.62	11.78
	(b) Non-current investments	55.49	5.32
	(d) Long-term loans and advances	31.28	31.50
	(e) Other non-current assets	0.00	0.00
		2263.12	2332.49

For Medicamen Biotech Ltd.



 (B.K. Gupta)
 Managing Director

2 Current assets		
(a) Current investments	2.00	2.00
(b) Inventories	1283.71	1512.44
(c) Trade receivables	2040.51	1836.12
(d) Cash and Bank Balances	271.10	209.21
(e) Short-term loans and advances	406.11	412.91
(f) Other current assets	191.35	218.26
	4194.78	4190.93
TOTAL ASSETS	6457.89	6523.42

NOTES :

- The above results after being reviewed by the Audit Committee were taken on record by the Board at its Meeting held on 30th May, 2014. 2. The figures for the quarter ended 31st March, 2014 & 31st March, 2013 are the balancing figures between the audited figures in respect of respective full financial years and published year to date figures up to third quarter of the respective financial years.
- The figures are regrouped in previous year also, wherever considered necessary.

Place: Delhi
Date: 30.05.2014

For & on behalf of
Medigen Biotech Limited
Medigen Biotech Ltd.

(B.K. Gupta)
Managing Director